Shattuck Labs Stock (NASDAQ:STTK)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.82

52W Range

$0.69 - $4.99

50D Avg

$0.99

200D Avg

$1.30

Market Cap

$40.57M

Avg Vol (3M)

$271.93K

Beta

1.73

Div Yield

-

STTK Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

44

IPO Date

Oct 09, 2020

Website

STTK Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
License	$3.40M

Fiscal year ends in Dec 24 | Currency in USD

STTK Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$5.72M	$1.66M	$652.00K
Operating Income	$-80.57M	$-91.96M	$-103.33M
Net Income	$-75.41M	$-87.30M	$-100.56M
EBITDA	$-80.57M	$-87.61M	$-100.26M
Basic EPS	$-1.49	$-2.05	$-2.37
Diluted EPS	$-1.49	$-2.05	$-2.37

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 23Nov 10, 23 | 8:00 AM

Q4 22Feb 26, 23 | 4:45 PM

Q3 22Nov 12, 22 | 4:30 PM

Peer Comparison

Ticker	Company
FHTX	Foghorn Therapeutics Inc.
CCCC	C4 Therapeutics, Inc.
SPRB	Spruce Biosciences, Inc.
RZLT	Rezolute, Inc.
PRLD	Prelude Therapeutics Incorporated